Biologics for dengue prevention: up-to-date.
Adam T WaickmanKrista NewellTimothy P EndyStephen J ThomasPublished in: Expert opinion on biological therapy (2022)
The world needs a safe and efficacious tetravalent dengue vaccine capable of protecting multiple different populations across a broad age range and different flavivirus immunologic backgrounds. Safe and effective antivirals are also needed to prevent or attenuate dengue disease in the unvaccinated, in cases of vaccine failure, or in high-risk populations.
Keyphrases